PL2326350T3 - Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych - Google Patents
Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowychInfo
- Publication number
- PL2326350T3 PL2326350T3 PL09789284T PL09789284T PL2326350T3 PL 2326350 T3 PL2326350 T3 PL 2326350T3 PL 09789284 T PL09789284 T PL 09789284T PL 09789284 T PL09789284 T PL 09789284T PL 2326350 T3 PL2326350 T3 PL 2326350T3
- Authority
- PL
- Poland
- Prior art keywords
- taxane
- expressing
- compounds
- cancer cells
- resistant cancer
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 title 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9530008P | 2008-09-08 | 2008-09-08 | |
| US20539509P | 2009-01-20 | 2009-01-20 | |
| EP09789284.8A EP2326350B1 (en) | 2008-09-08 | 2009-09-08 | Compounds for killing psma-expressing, taxane-resistant cancer cells |
| PCT/US2009/005064 WO2010027513A2 (en) | 2008-09-08 | 2009-09-08 | Methods for killing psma-expressing, taxane-resistant cancer cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2326350T3 true PL2326350T3 (pl) | 2014-03-31 |
Family
ID=41632348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09789284T PL2326350T3 (pl) | 2008-09-08 | 2009-09-08 | Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9242012B2 (pl) |
| EP (2) | EP2326350B1 (pl) |
| DK (1) | DK2326350T3 (pl) |
| ES (1) | ES2438495T3 (pl) |
| PL (1) | PL2326350T3 (pl) |
| PT (1) | PT2326350E (pl) |
| WO (1) | WO2010027513A2 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| EP3656403B1 (en) | 2007-08-17 | 2022-05-11 | Purdue Research Foundation | Preparation process of psma binding ligand-linker conjugates |
| PL2326350T3 (pl) | 2008-09-08 | 2014-03-31 | Psma Dev Company L L C | Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych |
| CA2769444A1 (en) | 2009-05-19 | 2010-11-25 | Aic Blab Company | Composite current collector and methods therefor |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| AU2011325893B2 (en) | 2010-11-12 | 2016-01-14 | Inovio Pharmaceuticals, Inc | Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same |
| WO2012138691A2 (en) * | 2011-04-04 | 2012-10-11 | Children's Medical Center Corporation | Diagnosis and treatment of taxane-resistant cancers |
| MX355908B (es) | 2011-04-22 | 2018-05-04 | Aptevo Res & Development Llc | Proteinas que se unen al antigeno de membrana especifico de prostata y composiciones y metodos relacionados. |
| WO2013185117A1 (en) * | 2012-06-07 | 2013-12-12 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| KR20150023729A (ko) * | 2012-06-14 | 2015-03-05 | 암브룩스, 인코포레이티드 | 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체 |
| MX2015006109A (es) | 2012-11-15 | 2016-02-05 | Endocyte Inc | Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma. |
| GEP20237497B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2015057250A1 (en) * | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| JP6908964B2 (ja) * | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| EP3777898B1 (en) | 2013-11-14 | 2025-01-01 | Endocyte, Inc. | Compounds for positron emission tomography |
| US20150147339A1 (en) | 2013-11-15 | 2015-05-28 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| DK3347054T3 (da) * | 2015-09-11 | 2021-07-19 | Genmab As | Dosisregimer til anti-TF-antistoflægemiddelkonjugater |
| EP3352760B1 (en) | 2015-09-21 | 2026-03-11 | Aptevo Research and Development LLC | Cd3 binding polypeptides |
| WO2018187791A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| WO2019204335A1 (en) | 2018-04-17 | 2019-10-24 | Endocyte, Inc. | Methods of treating cancer |
| CA3128081A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5756825A (en) | 1992-09-08 | 1998-05-26 | Safavy; Ahmad | Hydroxamic acid-based bifunctional chelating compounds |
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US7070782B1 (en) | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| EP1757694A3 (en) | 1992-11-05 | 2008-02-27 | Sloan Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5935818A (en) | 1995-02-24 | 1999-08-10 | Sloan-Kettering Institute For Cancer Research | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof |
| US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| DE69635801T2 (de) | 1995-02-24 | 2006-11-02 | Sloan-Kettering Institute For Cancer Research | Prostataspezifisches membranes antigen und seine anwendungen |
| US5994292A (en) | 1995-05-31 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon-inducible protein 10 is a potent inhibitor of angiogenesis |
| US5773292A (en) | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
| US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| US20040253246A1 (en) | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
| AU725583B2 (en) | 1996-03-25 | 2000-10-12 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen |
| US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US7381407B1 (en) | 1996-03-25 | 2008-06-03 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US5804602A (en) | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| EP0973540B1 (en) | 1997-02-25 | 2005-11-02 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| US6200765B1 (en) | 1998-05-04 | 2001-03-13 | Pacific Northwest Cancer Foundation | Non-invasive methods to detect prostate cancer |
| ES2299256T3 (es) | 1998-05-26 | 2008-05-16 | Sloan-Kettering Institute For Cancer Research | Constructos que emiten particulas alfa y sus usos. |
| EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF |
| CA2370033A1 (en) | 1999-04-09 | 2000-10-19 | Sloan-Kettering Institute For Cancer Research | Dna encoding the prostate-specific membrane antigen-like gene and uses thereof |
| EP1553414A1 (en) | 1999-04-13 | 2005-07-13 | Medarex, Inc. | Methods for the diagnosis and treatment of metastatic prostate tumors |
| AU775583B2 (en) | 1999-04-13 | 2004-08-05 | Medarex, Inc. | Methods for the diagnosis and treatment of metastatic prostate tumors |
| EP1208232A4 (en) | 1999-06-10 | 2003-01-15 | Sloan Kettering Inst Cancer | MARKERS FOR PROSTATE CANCER |
| DE60031279T2 (de) | 1999-07-29 | 2007-05-16 | Medarex, Inc. | Humane monoklonale antikörper gegen prostata spezifisches membranantigen |
| EP1710256A1 (en) | 1999-07-29 | 2006-10-11 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen |
| EP1221053A4 (en) | 1999-09-13 | 2004-12-22 | Neil H Bander | METHOD FOR INSULATING PROSTATIC EPITHELIC CELLS FROM SPERM |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| ATE553131T1 (de) | 2000-05-08 | 2012-04-15 | Celldex Res Corp | Humane monoklonale antikörper gegen dendritische zellen |
| US20030175247A1 (en) | 2000-05-12 | 2003-09-18 | Michael Salgaller | Method to increase class I presentation of exogenous antigens by human dendritic cells |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2002096460A1 (en) | 2001-05-30 | 2002-12-05 | Cornell Research Foundation, Inc. | Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer |
| US7666414B2 (en) | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| EP2277542B1 (en) | 2001-06-01 | 2014-04-16 | Cornell Research Foundation Inc. | Modified antibodies to prostrate-specific membrane antigen and uses thereof |
| IL159422A0 (en) | 2001-09-20 | 2004-06-01 | Cornell Res Foundation Inc | Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| AU2002356844C1 (en) | 2001-10-23 | 2010-03-04 | Amgen Fremont Inc. | PSMA antibodies and protein multimers |
| AU2002367377A1 (en) | 2001-12-26 | 2003-07-24 | Sloan Kettering Institute For Cancer Research | Dna immunization with libraries of minigenes encoding degenerate variants of major histocompatibility class i restricted epitopes |
| AU2003210719A1 (en) | 2002-01-28 | 2003-09-02 | Sloan-Kettering Institute For Cancer Research | Identification of mutant antigens with enhanced immunogenicity |
| WO2003064606A2 (en) | 2002-01-28 | 2003-08-07 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| DK2357006T3 (en) | 2002-07-31 | 2015-12-21 | Seattle Genetics Inc | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| US20040136998A1 (en) | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
| ATE408712T1 (de) | 2003-01-10 | 2008-10-15 | Millennium Pharm Inc | Verfahren zur bestimmung des wiederauftretens von prostata krebs |
| BRPI0407002A (pt) | 2003-02-10 | 2006-01-10 | Northwest Biotherapeutics Inc | Células cultivadas que apresentam antìgeno cd14+ |
| EP2289559B1 (en) | 2003-02-20 | 2014-02-12 | Seattle Genetics, Inc. | Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| US20050202020A1 (en) | 2004-01-09 | 2005-09-15 | Jeffrey Ross | Diagnosing and treating cancer |
| ES2533695T3 (es) | 2004-03-02 | 2015-04-14 | Seattle Genetics, Inc. | Anticuerpos cargados parcialmente y métodos para su conjugación |
| WO2005094882A1 (en) | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7378504B2 (en) | 2004-06-03 | 2008-05-27 | Medarex, Inc. | Human monoclonal antibodies to Fc gamma receptor I (CD64) |
| US20060057626A1 (en) | 2004-09-03 | 2006-03-16 | Nichol Geoffrey M | Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy |
| JP2008516586A (ja) | 2004-09-30 | 2008-05-22 | メダレックス インコーポレーティッド | Ｆｃγ受容体ＩＩ（ＣＤ３２）に対するヒトモノクローナル抗体 |
| CA2586909A1 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| JP2008526979A (ja) | 2005-01-14 | 2008-07-24 | サイトジェン コーポレーション | 抗ｐｓｍａ抗体による併用癌治療法 |
| AU2006214032B2 (en) | 2005-02-18 | 2012-03-08 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
| HRP20120709T1 (hr) | 2005-02-18 | 2012-10-31 | Medarex, Inc. | Humano monoklonsko protutijelo za prostata-specifiäśni membranski antigen (psma) |
| WO2006110745A2 (en) | 2005-04-08 | 2006-10-19 | Cytogen Corporation | Conjugated anti-psma antibodies |
| CN103127523A (zh) | 2005-06-20 | 2013-06-05 | Psma开发有限公司 | Psma抗体-药物缀合物 |
| EP1917020B1 (en) | 2005-07-07 | 2016-05-25 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| PL1912671T3 (pl) | 2005-07-18 | 2018-02-28 | Seattle Genetics, Inc. | Koniugaty beta-glukuronid-linker-lek |
| CA2623652C (en) | 2005-09-26 | 2013-11-26 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
| WO2007059190A2 (en) | 2005-11-14 | 2007-05-24 | Psma Development Company, Llc. | Compositions of and methods of using stabilized psma dimers |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| PL2326350T3 (pl) | 2008-09-08 | 2014-03-31 | Psma Dev Company L L C | Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych |
-
2009
- 2009-09-08 PL PL09789284T patent/PL2326350T3/pl unknown
- 2009-09-08 EP EP09789284.8A patent/EP2326350B1/en not_active Not-in-force
- 2009-09-08 PT PT97892848T patent/PT2326350E/pt unknown
- 2009-09-08 DK DK09789284.8T patent/DK2326350T3/da active
- 2009-09-08 EP EP13182516.8A patent/EP2727606A3/en not_active Withdrawn
- 2009-09-08 WO PCT/US2009/005064 patent/WO2010027513A2/en not_active Ceased
- 2009-09-08 ES ES09789284.8T patent/ES2438495T3/es active Active
-
2011
- 2011-02-17 US US13/030,105 patent/US9242012B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2326350T3 (da) | 2013-12-16 |
| WO2010027513A2 (en) | 2010-03-11 |
| HK1159474A1 (en) | 2012-08-03 |
| EP2727606A3 (en) | 2015-09-23 |
| EP2727606A2 (en) | 2014-05-07 |
| EP2326350B1 (en) | 2013-09-04 |
| EP2326350A2 (en) | 2011-06-01 |
| ES2438495T3 (es) | 2014-01-17 |
| PT2326350E (pt) | 2013-12-10 |
| WO2010027513A3 (en) | 2010-06-10 |
| US9242012B2 (en) | 2016-01-26 |
| US20110250216A1 (en) | 2011-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2326350T3 (pl) | Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych | |
| IL199682A0 (en) | Formulations for cancer treatment | |
| SI2384326T1 (sl) | Pirolo(2,3-d)pirimidinske spojine | |
| PL2231311T3 (pl) | Układ obróbki emisji | |
| ZA201105377B (en) | Imine compounds for combating invertebrated pests | |
| EP2135507A4 (en) | DISINFECTANT | |
| AP2011005533A0 (en) | Anastomat for circumcision. | |
| EP2141990A4 (en) | ACTIVE COMPOUNDS ON 11BETA-HSD1 | |
| GB0704906D0 (en) | Fungicides | |
| ZA201001228B (en) | Fungicidal 2-alkylthio-2-quinolinyloxy-acetamide derivatives | |
| SI2358697T1 (sl) | Spojine izoindolina za uporabo pri zdravljenju raka | |
| AP2011005706A0 (en) | New compounds. | |
| PL2136629T3 (pl) | Fenoksyfenyloamidyny jako fungicydy | |
| GB0800407D0 (en) | Fungicides | |
| IL212070A0 (en) | 7-piperidinoalkyl-3,4-dihydroquinolone derivative | |
| IL209690A0 (en) | Sulfoximinamide compounds for combating animal pests | |
| DE602008004167D1 (en) | 6-phenyl-1h-imidazoä4,5-cü-pyridin-4-carbonitrilderivate als cathepsin-hemmer | |
| IL199771A0 (en) | Active substance combination | |
| IL200756A (en) | Conjugated hydroxypolymer polymers with cancer cell killing capabilities | |
| GB0707556D0 (en) | Treatment for cancer | |
| GB0821721D0 (en) | Antimicrobial therapy | |
| GB0809046D0 (en) | Cancer treatment | |
| EP2356230A4 (en) | LGF / GPSM2 GENERAL WITH CANCER | |
| AU2008258879C1 (en) | Fungicidal substance combinations | |
| AU2007903039A0 (en) | Animal Guide |